WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences

Search Results -

Term	Documents
DETECT.USPT.	249145
DETECTS.USPT.	167899
BREAST.USPT.	15374
BREASTS.USPT.	1724
CANCER.USPT.	36906
CANCERS.USPT.	9277
CARCINOMA.USPT.	11937
CARCINOMAS.USPT.	4533
(8 AND (DETECT ADJ3 (BREAST ADJ (CARCINOMA OR CANCER)))).USPT.	18

Database: US Patents Full Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search: `18 and (detect adj3 (breast adj (cancer or carcinoma)))` Clear

Search History

Today's Date: 10/19/2000

DB Name	Query	Hit Count	Set Name
USPT	l8 and (detect adj3 (breast adj (cancer or carcinoma)))	18	L9
USPT	l7 and (detect same (breast adj (cancer or carcinoma)))	146	L8
USPT	l6 and hybrid$5	1071	L7
USPT	l5 and pcr	1188	L6
USPT	l4 and amplif$8	1414	L5
USPT	l3 and (probe or primer)	1864	L4
USPT	l2 and (nucleotide or nucleic or dna or cdna)	2699	L3
USPT	l1 and detect$3	4174	L2
USPT	breast adj (cancer or carcinoma)	6206	L1

WEST

Generate Collection

Search Results - Record(s) 1 through 18 of 18 returned.

☐ 1. Document ID: US 6124104 A

L9: Entry 1 of 18 File: USPT Sep 26, 2000

US-PAT-NO: 6124104
DOCUMENT-IDENTIFIER: US 6124104 A

TITLE: Chromosome 13-linked breast cancer susceptibility gene

DATE-ISSUED: September 26, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tavtigian; Sean V.	Salt Lake City	UT	N/A	N/A
Kamb; Alexander	Salt Lake City	UT	N/A	N/A
Simard; Jacques	St. Augustin de Desmuures	N/A	N/A	CAX
Couch; Fergus	St. Davids	PA	N/A	N/A
Rommens; Johanna M.	Toronto	N/A	N/A	CAX
Weber; Barbara L.	Merion	PA	N/A	N/A

US-CL-CURRENT: 435/7.2; 435/320.1, 435/325, 435/366, 530/828, 536/23.1, 536/23.5

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA2 gene for mutations, which are useful for diagnosing the predisposition to breast cancer.

7 Claims, 11 Drawing figures Exemplary Claim Number: 1,7
Number of Drawing Sheets: 9

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Drawi Desc | Image

☐ 2. Document ID: US 6057105 A

L9: Entry 2 of 18 File: USPT May 2, 2000

US-PAT-NO: 6057105
DOCUMENT-IDENTIFIER: US 6057105 A

TITLE: Detection of melanoma or breast metastasis with a multiple marker assay

DATE-ISSUED: May 2, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hoon; Dave S. B.	Los Angeles	CA	N/A	N/A
Conrad; Andrew J.	Los Angeles	CA	N/A	N/A
Schmid; Peter	Los Angeles	CA	N/A	N/A

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2, 536/23.5, 536/24.31, 536/24.33, 536/25.3

ABSTRACT:

Methods for detecting metastasis of melanoma and breast cancer cells, detecting subclinical metastasis, and monitoring treatment are disclosed. Kits for use in such methods also are disclosed. The methods provide for the detection of nucleic acids corresponding to multiple melanoma or breast cancer specific markers using template dependent amplification processes. Methods using multiple markers provide increased sensitivity over existing methods.

85 Claims, 1 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 1

☐ 3. Document ID: US 6037129 A

L9: Entry 3 of 18 File: USPT Mar 14, 2000

US-PAT-NO: 6037129
DOCUMENT-IDENTIFIER: US 6037129 A

TITLE: Multi-marker RT-PCR panel for detecting metastatic breast cancer

DATE-ISSUED: March 14, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cole; David J.	Mt. Pleasant	SC	N/A	N/A
Baron; Paul L.	Charleston	SC	N/A	N/A
O'Brien; Paul H.	Charleston	SC	N/A	N/A

US-CL-CURRENT: 435/6; 536/24.3

ABSTRACT:

A method of detecting the metastasis of primary breast cancer to a lymph node is provided, comprising detecting, in lymph node tissue, the presence of a nucleic acid of c-myc, PIP or keratin-19. The presence of any one of these nucleic acids in lymph node tissue is associated with metastatic breast cancer. The presence of one or more of these markers in lymph node tissue or other tissue indicates that cells from the primary tumor have migrated from the breast tissue to the lymph node or other tissue. Also provided is a method of predicting the histopathologic stage of a cancer in a patient without having to perform a histopathologic analysis, comprising detecting, in lymph node tissue from the patient, the presence of a nucleic acid of c-myc, the presence of a nucleic acid of c-myc being correlated with stage I cancer as determined by histopathology. Alternatively, the absence of a nucleic acid of PIP and the absence of a nucleic acid of keratin-19 are correlated with stage I cancer as determined by histopathology. In another embodiment, the presence of a nucleic acid of PIP is correlated with stages later than stage I cancer as determined by histopathology. Further, the presence of a nucleic acid of keratin-19 is correlated with stages later than stage I cancer as determined by histopathology. A method of predicting survival time of cancer patients is also provided, comprising detecting, in lymph node tissue from the patient, the presence of a nucleic acid of c-myc, PIP or keratin-19. The presence of a nucleic acid of any of c-myc, PIP or keratin-19 is correlated with a shorter average survival time compared with the presence of none of the nucleic acids.

10 Claims, 3 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 3

☐ 4. Document ID: US 6033857 A

L9: Entry 4 of 18 File: USPT Mar 7, 2000

US-PAT-NO: 6033857
DOCUMENT-IDENTIFIER: US 6033857 A

TITLE: Chromosome 13-linked breast cancer susceptibility gene

DATE-ISSUED: March 7, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tavtigian; Sean V.	Salt Lake City	UT	N/A	N/A
Kamb; Alexander	Salt Lake City	UT	N/A	N/A
Simard; Jacques	St. Augustin de Desmuures	N/A	N/A	CAX
Couch; Fergus	St. Davids	PA	N/A	N/A
Rommens; Johanna M.	Toronto	N/A	N/A	CAX
Weber; Barbara L.	Merion	PA	N/A	N/A

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/7.2, 536/23.1, 536/23.5

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA2 gene for mutations, which are useful for diagnosing the predisposition to breast cancer.

8 Claims, 11 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 9

☐ 5. Document ID: US 5939258 A

L9: Entry 5 of 18 File: USPT Aug 17, 1999

US-PAT-NO: 5939258
DOCUMENT-IDENTIFIER: US 5939258 A

TITLE: Methods of detecting micrometastasis of prostate cancer

DATE-ISSUED: August 17, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Croce; Carlo	Philadelphia	PA	N/A	N/A
Gomella; Leonard	Sewell	NJ	N/A	N/A
Mulholland; S. Grant	Gladwyne	PA	N/A	N/A
Moreno; Jose G.	Wayne	PA	N/A	N/A
Fischer; Rainer	Aachen-Leniers	N/A	N/A	DEX

US-CL-CURRENT: 435/6; 435/91.2

ABSTRACT:

A method of diagnosing prostate micrometastasis is provided by the present invention whereby nucleic acids from a tissue sample from a patient are isolated, nucleic acids from the tissue sample specific for prostate cancer are amplified, or a signal generated by hybridization of a probe specific to a prostate cancer specific nucleic acid is amplified; and detection of amplified nucleic acids is indicative of micrometastasis of prostate cancer.

13 Claims, 5 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

---

☐ 6. Document ID: US 5914238 A

L9: Entry 6 of 18 File: USPT Jun 22, 1999

US-PAT-NO: 5914238
DOCUMENT-IDENTIFIER: US 5914238 A

TITLE: Materials and methods for detection of breast cancer

DATE-ISSUED: June 22, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Keesee; Susan K.	Harvard	MA	N/A	N/A
Obar; Robert	Walpole	MA	N/A	N/A
Wu; Ying-Jye	Framingham	MA	N/A	N/A

US-CL-CURRENT: 435/7.23; 435/7.1, 435/7.2, 436/63, 436/64

ABSTRACT:

Provided are materials and methods for early diagnosis of breast cancer by detection of breast cancer-associated proteins.

11 Claims, 2 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 7. Document ID: US 5871917 A

L9: Entry 7 of 18 File: USPT Feb 16, 1999

US-PAT-NO: 5871917
DOCUMENT-IDENTIFIER: US 5871917 A

TITLE: Identification of differentially methylated and mutated nucleic acids

DATE-ISSUED: February 16, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Duffy; Hao-peng Xu	Centerport	NY	N/A	N/A

US-CL-CURRENT: 435/6; 435/91.2, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

The present invention provides Methyl- (or Mutant-) Differential Display (MDD) methods and nucleic acid probes for detecting mutations and the methylation patterns of nucleic acids. The methods of the present invention are particularly useful for detecting and isolating genomic DNA fragments which are near coding and regulatory regions of genes and which are differentially mutated or methylated relative to the corresponding DNA from normal cells. Genes are frequently not methylated in the cells where they are expressed but are methylated in cell types where they are not expressed. Moreover, tumor cell DNA is frequently methylated to a different extent and in different regions than is the DNA of normal cells. The present invention is used for identifying which regions of the genome are methylated or mutated in different cell types, including cancerous cell types. The present invention is also used for diagnosing whether a tissue sample is cancerous, and whether that cancerous condition is non-metastatic or metastatic.

79 Claims, 19 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 8. Document ID: US 5837492 A

L9: Entry 8 of 18 File: USPT Nov 17, 1998

US-PAT-NO: 5837492
DOCUMENT-IDENTIFIER: US 5837492 A

TITLE: Chromosome 13-linked breast cancer susceptibility gene

DATE-ISSUED: November 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tavtigian; Sean V.	Salt Lake City	UT	N/A	N/A
Kamb; Alexander	Salt Lake City	UT	N/A	N/A
Simard; Jacques	St. Augustin de Desmuures	N/A	N/A	CAX
Couch; Fergus	St. Davids	PA	N/A	N/A
Rommens; Johanna M.	Toronto	N/A	N/A	CAX
Weber; Barbara L.	Merion	PA	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/320.1, 435/375, 530/828

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast cancer predisposing gene (BRCA2), some mutant alleles of which cause susceptibility to cancer, in particular breast cancer. More specifically, the invention relates to germline mutations in the BRCA2 gene and their use in the diagnosis of predisposition to breast cancer. The present invention further relates to somatic mutations in the BRCA2 gene in human breast cancer and their use in the diagnosis and prognosis of human breast cancer. Additionally, the invention relates to somatic mutations in the BRCA2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA2 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA2 gene for mutations, which are useful for diagnosing the predisposition to breast cancer.

30 Claims, 11 Drawing figures Exemplary Claim Number: 1,16,21,29
Number of Drawing Sheets: 9

☐ 9. Document ID: US 5753441 A

L9: Entry 9 of 18 File: USPT May 19, 1998

US-PAT-NO: 5753441
DOCUMENT-IDENTIFIER: US 5753441 A

TITLE: 170-linked breast and ovarian cancer susceptibility gene

DATE-ISSUED: May 19, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Skolnick; Mark H.	Salt Lake City	UT	N/A	N/A
Goldgar; David E.	Salt Lake City	UT	N/A	N/A
Miki; Yoshio	Salt Lake City	UT	N/A	N/A
Swenson; Jeff	Salt Lake City	UT	N/A	N/A
Kamb; Alexander	Salt Lake City	UT	N/A	N/A
Harshman; Keith D.	Salt Lake City	UT	N/A	N/A
Shattuck-Eidens; Donna M.	Salt Lake City	UT	N/A	N/A
Tavtigian; Sean V.	Salt Lake City	UT	N/A	N/A
Wiseman; Roger W.	Durham	NC	N/A	N/A
Futreal; P. Andrew	Durham	NC	N/A	N/A

US-CL-CURRENT: 435/6; 424/1.11, 435/4, 435/7.1, 435/7.2, 435/7.9, 435/91.1, 435/91.2, 436/500, 436/548, 530/387.2, 530/388.1, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

37 Claims, 19 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 18

☐ 10. Document ID: US 5747282 A

L9: Entry 10 of 18 File: USPT May 5, 1998

US-PAT-NO: 5747282
DOCUMENT-IDENTIFIER: US 5747282 A

TITLE: 17Q-linked breast and ovarian cancer susceptibility gene

DATE-ISSUED: May 5, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Skolnick; Mark H.	Salt Lake City	UT	N/A	N/A
Goldgar; David E.	Salt Lake City	UT	N/A	N/A
Miki; Yoshio	Salt Lake City	UT	N/A	N/A
Swenson; Jeff	Salt Lake City	UT	N/A	N/A
Kamb; Alexander	Salt Lake City	UT	N/A	N/A
Harshman; Keith D.	Salt Lake City	UT	N/A	N/A
Shattuck-Eidens; Donna M.	Salt Lake City	UT	N/A	N/A
Tavtigian; Sean V.	Salt Lake City	UT	N/A	N/A
Wiseman; Roger W.	Durham	NC	N/A	N/A
Futreal; P. Andrew	Durham	NC	N/A	N/A

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/6, 536/23.5, 536/24.31, 536/24.33

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

20 Claims, 10 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 18

☐ 11. Document ID: US 5728579 A

L9: Entry 11 of 18 File: USPT Mar 17, 1998

US-PAT-NO: 5728579
DOCUMENT-IDENTIFIER: US 5728579 A

TITLE: DNA encoding Mat-8

DATE-ISSUED: March 17, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Morrison; Briggs W.	Westwood	MA	N/A	N/A
Leder; Philip	Chestnut Hill	MA	N/A	N/A

US-CL-CURRENT: 435/325; 435/252.3, 435/255.1, 435/320.1, 536/23.5

ABSTRACT:

A novel chloride channel protein found in human breast cancer cells is disclosed. The chloride channel protein, called Mat-8, serves as a useful diagnostic reagent for the detection of breast cancer. The Mat-8 protein and chloride channel proteins generally, are useful therapeutic targets for the treatment of breast cancer.

9 Claims, 10 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 6

☐ 12. Document ID: US 5710001 A

L9: Entry 12 of 18 File: USPT Jan 20, 1998

US-PAT-NO: 5710001
DOCUMENT-IDENTIFIER: US 5710001 A

TITLE: 17q-linked breast and ovarian cancer susceptibility gene

DATE-ISSUED: January 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Skolnick; Mark H.	Salt Lake City	UT	N/A	N/A
Goldgar; David E.	Salt Lake City	UT	N/A	N/A
Miki; Yoshio	Salt Lake City	UT	N/A	N/A
Swenson; Jeff	Salt Lake City	UT	N/A	N/A
Kamb; Alexander	Salt Lake City	UT	N/A	N/A
Harshman; Keith D.	Salt Lake City	UT	N/A	N/A
Shattuck-Eidens; Donna M.	Salt Lake City	UT	N/A	N/A
Tavtigian; Sean V.	Salt Lake City	UT	N/A	N/A
Wiseman; Roger W.	Durham	NC	N/A	N/A
Futreal; P. Andrew	Durham	NC	N/A	N/A

US-CL-CURRENT: 435/6; 435/7.1, 435/7.9, 435/91.2, 530/300, 530/350, 530/388.1, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

35 Claims, 19 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 18

☐ 13. Document ID: US 5709999 A

L9: Entry 13 of 18 File: USPT Jan 20, 1998

US-PAT-NO: 5709999
DOCUMENT-IDENTIFIER: US 5709999 A

TITLE: Linked breast and ovarian cancer susceptibility gene

DATE-ISSUED: January 20, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shattuck-Eidens; Donnà M.	Salt Lake City	UT	N/A	N/A
Simard; Jacques	St. Augustin de Desmaures	N/A	N/A	CAX
Durocher; Francine	Ste-Foy	N/A	N/A	CAX
Emi; Mitsuuru	Tokyo	N/A	N/A	JPX
Nakamura; Yusuke	Yokohama	N/A	N/A	JPX

US-CL-CURRENT: 435/6; 435/91.2, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

35 Claims, 19 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 18

☐ 14. Document ID: US 5693473 A

L9: Entry 14 of 18 File: USPT Dec 2, 1997

US-PAT-NO: 5693473
DOCUMENT-IDENTIFIER: US 5693473 A

TITLE: Linked breast and ovarian cancer susceptibility gene

DATE-ISSUED: December 2, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Shattuck-Eidens; Donna M.	Salt Lake City	UT	N/A	N/A
Simard; Jacques	Quebec	N/A	N/A	CAX
Durocher; Francine	Ste-Foy	N/A	N/A	CAX
Emi; Mitsuuru	Tokoyo	N/A	N/A	JPX
Nakamura; Yusuke	Yokohama	N/A	N/A	JPX

US-CL-CURRENT: 435/6; 435/91.2, 536/23.1, 536/24.3, 536/24.33

ABSTRACT:

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human breast and ovarian cancer predisposing gene (BRCA1), some mutant alleles of which cause susceptibility to cancer, in particular breast and ovarian cancer. More specifically, the invention relates to germline mutations in the BRCA1 gene and their use in the diagnosis of predisposition to breast and ovarian cancer. The present invention further relates to somatic mutations in the BRCA1 gene in human breast and ovarian cancer and their use in the diagnosis and prognosis of human breast and ovarian cancer. Additionally, the invention relates to somatic mutations in the BRCA1 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the BRCA1 gene, including gene therapy, protein replacement therapy and protein mimetics. The invention further relates to the screening of drugs for cancer therapy. Finally, the invention relates to the screening of the BRCA1 gene for mutations, which are useful for diagnosing the predisposition to breast and ovarian cancer.

14 Claims, 19 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 18

☐ 15. Document ID: US 5688649 A

L9: Entry 15 of 18 File: USPT Nov 18, 1997

US-PAT-NO: 5688649
DOCUMENT-IDENTIFIER: US 5688649 A

TITLE: Methods of detecting micrometastasis of prostate cancer

DATE-ISSUED: November 18, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Croce; Carlo	Philadelphia	PA	N/A	N/A
Gomella; Leonard	Sewell	NJ	N/A	N/A
Mulholland; S. Grant	Birchrunville	PA	N/A	N/A
Moreno; Jose G.	Wayne	PA	N/A	N/A
Fischer; Rainer	Aachen-Leniers	N/A	N/A	DEX

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2, 536/23.1, 536/23.2, 536/24.33

ABSTRACT:

A method of diagnosing prostate metastasis is provided by the present invention whereby RNA from a patient's blood is isolated and amplified using a pair of primers which are complementary to regions of the prostate specific antigen gene. The presence or absence of amplified RNA is detected and the presence of amplified RNA is indicative micrometastasis of prostate cancer.

9 Claims, 1 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 1

☐ 16. Document ID: US 5674682 A

L9: Entry 16 of 18 File: USPT Oct 7, 1997

US-PAT-NO: 5674682
DOCUMENT-IDENTIFIER: US 5674682 A

TITLE: Nucleic acid primers for detecting micrometastasis of prostate cancer

DATE-ISSUED: October 7, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Croce; Carlo	Philadelphia	PA	N/A	N/A
Gomella; Leonard	Sewell	NJ	N/A	N/A
Mulholland; S. Grant	Gladwyne	PA	N/A	N/A
Moreno; Jose G.	Wayne	PA	N/A	N/A
Fischer; Rainer	Aachen-Leniers	N/A	N/A	DEX

US-CL-CURRENT: 435/6; 435/810, 435/91.1, 435/91.2, 536/23.1, 536/24.31, 536/24.33, 536/24.5

ABSTRACT:

Oligonucleotides for and a method of diagnosing prostate micrometastasis are provided by the present invention whereby nucleic acids from a tissue sample from a patient are isolated, nucleic acids from the tissue sample specific for prostate cancer are amplified, or a signal generated by hybridization of a probe specific to a prostate cancer specific nucleic acid is amplified; and detection of amplified nucleic acids is indicative of micrometastasis of prostate cancer.

8 Claims, 8 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

---

☐ 17. Document ID: US 5648215 A

L9: Entry 17 of 18 File: USPT Jul 15, 1997

US-PAT-NO: 5648215
DOCUMENT-IDENTIFIER: US 5648215 A

TITLE: Telomerase diagnostic methods

DATE-ISSUED: July 15, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
West; Michael D.	San Carlos	CA	N/A	N/A
Shay; Jerry	Dallas	TX	N/A	N/A
Wright; Woodring E.	Arlington	TX	N/A	N/A

US-CL-CURRENT: 435/6; 435/15, 435/91.1, 435/91.5, 436/64

ABSTRACT:

The presence of telomerase activity in a human somatic tissue or cell sample is positively correlated with the presence of cancer and can be used to diagnose the course of disease progression in a patient.

12 Claims, 9 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

☐ 18. Document ID: US 5506106 A

L9: Entry 18 of 18 File: USPT Apr 9, 1996

US-PAT-NO: 5506106
DOCUMENT-IDENTIFIER: US 5506106 A

TITLE: Methods of detecting micrometastasis of prostate cancer

DATE-ISSUED: April 9, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Croce; Carlo	Philadelphia	PA	N/A	N/A
Gomella; Leonard	Sewell	NJ	N/A	N/A
Mulholland; S. Grant	Gladwynne	PA	N/A	N/A
Moreno; Jose G.	Wayne	PA	N/A	N/A
Fischer; Rainer	Aachen-Leniers	N/A	N/A	DEX

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2, 536/23.1, 536/23.2, 536/24.33

ABSTRACT:

A method of diagnosing prostate metastasis is provided by the present invention whereby RNA from a patient's blood is isolated and amplified using a pair of primers which are complementary to regions of the prostate specific antigen gene. The presence or absence of amplified RNA is detected and the presence of amplified RNA is indicative micrometastasis of prostate cancer.

4 Claims, 1 Drawing figures Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc | Image

Generate Collection

Term	Documents
DETECT.USPT.	249145
DETECTS.USPT.	167899
BREAST.USPT.	15374
BREASTS.USPT.	1724
CANCER.USPT.	36906
CANCERS.USPT.	9277
CARCINOMA.USPT.	11937
CARCINOMAS.USPT.	4533
(8 AND (DETECT ADJ3 (BREAST ADJ (CARCINOMA OR CANCER)))).USPT.	18

Display 20 Documents, starting with Document: 18

Display Format: REV Change Format